These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 19626586)

  • 1. Outcome prediction and risk assessment by quantitative pyrosequencing methylation analysis of the SFN gene in advanced stage, high-risk, neuroblastic tumor patients.
    Banelli B; Bonassi S; Casciano I; Mazzocco K; Di Vinci A; Scaruffi P; Brigati C; Allemanni G; Borzì L; Tonini GP; Romani M
    Int J Cancer; 2010 Feb; 126(3):656-68. PubMed ID: 19626586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TrkA expression in peripheral neuroblastic tumors: prognostic significance and biological relevance.
    Shimada H; Nakagawa A; Peters J; Wang H; Wakamatsu PK; Lukens JN; Matthay KK; Siegel SE; Seeger RC
    Cancer; 2004 Oct; 101(8):1873-81. PubMed ID: 15386308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group.
    Goto S; Umehara S; Gerbing RB; Stram DO; Brodeur GM; Seeger RC; Lukens JN; Matthay KK; Shimada H
    Cancer; 2001 Nov; 92(10):2699-708. PubMed ID: 11745206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Galectin-3 is a marker of favorable prognosis and a biologically relevant molecule in neuroblastic tumors.
    Veschi V; Petroni M; Bartolazzi A; Altavista P; Dominici C; Capalbo C; Boldrini R; Castellano A; McDowell HP; Pizer B; Frati L; Screpanti I; Gulino A; Giannini G
    Cell Death Dis; 2014 Mar; 5(3):e1100. PubMed ID: 24603328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High Oct4 expression: implications in the pathogenesis of neuroblastic tumours.
    Monferrer E; Burgos-Panadero R; Blanquer-Maceiras M; Cañete A; Navarro S; Noguera R
    BMC Cancer; 2019 Jan; 19(1):1. PubMed ID: 30606139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical potentials of methylator phenotype in stage 4 high-risk neuroblastoma: an open challenge.
    Banelli B; Merlo DF; Allemanni G; Forlani A; Romani M
    PLoS One; 2013; 8(5):e63253. PubMed ID: 23717404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aberrant stratifin overexpression is regulated by tumor-associated CpG demethylation in lung adenocarcinoma.
    Shiba-Ishii A; Noguchi M
    Am J Pathol; 2012 Apr; 180(4):1653-62. PubMed ID: 22310466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RSPH9 methylation pattern as a prognostic indicator in patients with non-muscle invasive bladder cancer.
    Yoon HY; Kim YJ; Kim JS; Kim YW; Kang HW; Kim WT; Yun SJ; Ryu KH; Lee SC; Kim WJ
    Oncol Rep; 2016 Feb; 35(2):1195-203. PubMed ID: 26575865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Downregulation of 14-3-3sigma in ovary, prostate and endometrial carcinomas is associated with CpG island methylation.
    Mhawech P; Benz A; Cerato C; Greloz V; Assaly M; Desmond JC; Koeffler HP; Lodygin D; Hermeking H; Herrmann F; Schwaller J
    Mod Pathol; 2005 Mar; 18(3):340-8. PubMed ID: 15257317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pathology of peripheral neuroblastic tumors].
    Wang L; He LJ; Shimada H
    Zhonghua Bing Li Xue Za Zhi; 2012 Apr; 41(4):283-8. PubMed ID: 22800533
    [No Abstract]   [Full Text] [Related]  

  • 11. [Prognostic factors in neuroblastoma. Usefulness of DNA analysis using flow cytometry on paraffin-embedded material].
    Massara FM; Tonello M; Forni M; Fruttero A; Lantermo R; Pugno F; Cordero di Montezemolo L; Ruà S
    Pediatr Med Chir; 1996; 18(2):141-8. PubMed ID: 8767575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High incidence of MYCN amplification in a Moroccan series of neuroblastic tumors: comparison to current biological data.
    Tabyaoui I; Tahiri-Jouti N; Serhier Z; El Maani K; Cherkaoui S; Al Zemmouri M; Othmani MB; Zamiati S
    Diagn Mol Pathol; 2013 Jun; 22(2):112-8. PubMed ID: 23628823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinicopathological characteristics of ganglioneuroma and ganglioneuroblastoma: a report from the CCG and COG.
    Okamatsu C; London WB; Naranjo A; Hogarty MD; Gastier-Foster JM; Look AT; LaQuaglia M; Maris JM; Cohn SL; Matthay KK; Seeger RC; Saji T; Shimada H
    Pediatr Blood Cancer; 2009 Oct; 53(4):563-9. PubMed ID: 19530234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclin D1 in pediatric neuroblastic tumors: A microarray analysis.
    Fagone P; Nicoletti F; Vecchio GM; Parenti R; Magro G
    Acta Histochem; 2015 Oct; 117(8):820-3. PubMed ID: 26510683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 14-3-3sigma gene silencing during melanoma progression and its role in cell cycle control and cellular senescence.
    Schultz J; Ibrahim SM; Vera J; Kunz M
    Mol Cancer; 2009 Jul; 8():53. PubMed ID: 19642975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemical expression of CD44s in human neuroblastic tumors: Moroccan experience and highlights on current data.
    Tabyaoui I; Tahiri-Jouti N; Serhier Z; Bennani-Othmani M; Sibai H; Itri M; Benchekroun S; Zamiati S
    Diagn Pathol; 2013 Feb; 8():39. PubMed ID: 23445749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of epigenetic inactivation of RASSF1A with poor outcome in human neuroblastoma.
    Yang Q; Zage P; Kagan D; Tian Y; Seshadri R; Salwen HR; Liu S; Chlenski A; Cohn SL
    Clin Cancer Res; 2004 Dec; 10(24):8493-500. PubMed ID: 15623630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The RNA component of telomerase as a marker of biologic potential and clinical outcome in childhood neuroblastic tumors.
    Maitra A; Yashima K; Rathi A; Timmons CF; Rogers BB; Shay JW; Gazdar AF
    Cancer; 1999 Feb; 85(3):741-9. PubMed ID: 10091748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genome-wide DNA methylation analysis of neuroblastic tumors reveals clinically relevant epigenetic events and large-scale epigenomic alterations localized to telomeric regions.
    Buckley PG; Das S; Bryan K; Watters KM; Alcock L; Koster J; Versteeg R; Stallings RL
    Int J Cancer; 2011 May; 128(10):2296-305. PubMed ID: 20669225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genome-wide analysis of CpG island methylation in bladder cancer identified TBX2, TBX3, GATA2, and ZIC4 as pTa-specific prognostic markers.
    Kandimalla R; van Tilborg AA; Kompier LC; Stumpel DJ; Stam RW; Bangma CH; Zwarthoff EC
    Eur Urol; 2012 Jun; 61(6):1245-56. PubMed ID: 22284968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.